...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular Physiology and Biochemistry >Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets
【24h】

Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets

机译：基于荟萃分析和癌症基因组图谱（TCGA）数据评估microRNA-203在实体瘤中的预后价值

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Background: It has been reported that miR-203 expression was aberrant in various types of cancers, and it could be used as a prognostic biomarker. Therefore, in this study, we aimed to evaluate the prognostic value of miR-203 expression in solid tumors by using meta-analysis and The Cancer Genome Atlas (TCGA) datasets. Methods: By doing a literature research in PubMed, Embase and the Cochrane Library (last update by December 2016), we were able to identify the studies assessing the prognostic role of miR-203 in various tumors. We then used TCGA datasets to validate the results of meta-analysis. Results:33 studies from 26 articles were qualified and enrolled in this meta-analysis. Pooled analyses showed that higher expression of miR-203 in tissues couldna€?t predict poor overall survival (OS) and progression-free survival (PFS) in solid tumors. However, the results of subgroup analyses revealed that the upregulation of tissue miR-203 expression was associated with poor OS in colorectal cancer (hazard ratio (HR)=1.81, 95% confidence intervals (CI) 1.31-2.49; P<0.001), pancreatic cancer (HR=1.19, 95% CI 1.09-1.31; P<0.001) and ovarian cancer (HR=1.85, 95% CI 1.45-2.37; P<0.001); but it had opposite association in liver cancer (HR=0.52, 95% CI 0.28-0.97; P=0.040) and esophageal cancer (HR=0.41, 95% CI 0.25-0.66; P<0.001). Based on TCGA datasets, we found the same results for pancreatic cancer and esophageal cancer, but not for colorectal cancer and liver cancer. Moreover, patients with high circulating miR-203 in blood had significantly poor OS and PFS in colorectal cancer and breast cancer. Conclusion: Our study showed that the prognostic values of tissue miR-203 varied in different tumor types. In addition, the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer.
机译：> 背景： 据报道，miR-203表达在各种类型的癌症中均异常，可以用作预后生物标志物。因此，在这项研究中，我们旨在通过使用荟萃分析和癌症基因组图谱（TCGA）数据评估miR-203在实体瘤中的预后价值。 方法： 通过在PubMed，Embase和Cochrane库中进行文献研究（最新更新于2016年12月），我们能够鉴定出评估miR的预后作用的研究-203在各种肿瘤中。然后，我们使用TCGA数据集来验证荟萃分析的结果。 结果： 来自26篇文章的33篇研究被纳入本荟萃分析并入选。汇总分析显示，miR-203在组织中的较高表达无法预测实体瘤的整体生存率（OS）和无进展生存期（PFS）。但是，亚组分析的结果表明，组织miR-203表达的上调与大肠癌的不良OS相关（危险比（HR）= 1.81，95％置信区间（CI）1.31-2.49; P < /i><0.001），胰腺癌（HR = 1.19，95％CI 1.09-1.31; P <0.001）和卵巢癌（HR = 1.85，95％CI 1.45-2.37; P <0.001）;但在肝癌（HR = 0.52，95％CI 0.28-0.97; P = 0.040）和食管癌（HR = 0.41，95％CI 0.25-0.66; P <0.001）。基于TCGA数据集，我们发现胰腺癌和食道癌的结果相同，但对于结直肠癌和肝癌却没有。此外，血液中循环miR-​​203含量高的患者在大肠癌和乳腺癌中的OS和PFS明显较差。 结论： 我们的研究表明，miR-203组织的预后价值在不同的肿瘤类型中有所不同。此外，血液中循环miR-​​203的上调与大肠癌和乳腺癌的不良预后有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号